Clinical Trials Browser

Carcinoma, Renal Cell × ciforadenant × Clear all

NCT05501054 2026-01-14

Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.

Phase 1/2 Active not recruiting

50 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03454451 2023-12-21

CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers

Phase 1 Completed

117 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02655822 2021-08-30

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Phase 1 Completed

502 enrolled

Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Prostatic Neoplasms